Evidence map›Paper›PMID 33981171›Full record

ArticleSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2021

Inclusion complex of clausenidin with hydroxypropyl-β-cyclodextrin: Improved physicochemical properties and anti-colon cancer activity.

Ashwaq Shakir Al-Abboodi, Warqa'a Muhammed Al-Sheikh, Eltayeb E M Eid, Faizul Azam, Mothanna Sadiq Al-Qubaisi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Biochemistry and biophysics reports · 2025
    Article
  3. Review
  4. Article
  5. 7-Geranyloxycinnamic Acid Isolated fromMolecules (Basel, Switzerland) · 2023
    Article
  6. Review
  7. Review
  8. Preparation, characterization,Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ashwaq Shakir Al-AbboodiBasic Science Branch, Faculty of Dentistry, University of Al-Qadisiyah, Al-Diwaniyah, Iraq.
Warqa'a Muhammed Al-SheikhBasic Science Branch, Faculty of Dentistry, University of Al-Qadisiyah, Al-Diwaniyah, Iraq.
Eltayeb E M EidDepratemnt of Pharmaceutical Chemistry and Pharmacognosy, Unaizah College of Pharmacy, Qassim University, Saudi Arabia.
Faizul AzamDepratemnt of Pharmaceutical Chemistry and Pharmacognosy, Unaizah College of Pharmacy, Qassim University, Saudi Arabia.
Mothanna Sadiq Al-QubaisiInstitute of Bioscience, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The long-term objective of the present study was to prepare, physicochemically characterize and determine the anticancer of clausenidin/hydroxypropyl-β-cyclodextrin (Clu/HPβCD) inclusion complex. We used differential scanning calorimetry, X-ray diffractometer, fourier transform infrared spectroscopy, ultraviolet-visible spectrophotometer and

Indexed as

Cell cycleClausenidinDrug releaseHydroxypropyl-β-cyclodextrinPhysicochemical characterizationReactive oxygen species

Identifiers

PMID33981171
PMCPMC8085604

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.